news
FDA approves Praluent for the treatment of high LDL cholesterol
26 August 2015 | By Victoria White
The US Food and Drug Administration (FDA) has approved Praluent (alirocumab) Injection - the first and only PCSK9 inhibitor approved in the US...
List view / Grid view
Cholesterol
news
EC approves Amgen’s cholesterol-lowering medication Repatha
21 July 2015 | By Victoria White
The EC has granted marketing authorisation for Repatha for the treatment of patients with uncontrolled cholesterol who require additional LDL-C reduction...
news
How a TV programme changed patients’ use of statins
15 June 2015 | By Victoria White
More than 60,000 Australians are estimated to have reduced or discontinued their use of prescribed statins following the airing of a TV programme...
news
Catabasis Pharmaceuticals announces preliminary Phase 1 data for hypercholesterolaemia product candidate CAT-2054
4 June 2015 | By Victoria White
Catabasis has announced preliminary Phase 1 clinical trial data for CAT-2054 - its candidate for the potential treatment of hypercholesterolaemia...
news
Results from Phase 2b study of CETP inhibitor TA-8995 published
3 June 2015 | By Victoria White
Dezima Pharma has announced the publication of the phase 2b TULIP study results with its CETP inhibitor, TA-8995, in patients with mild dyslipidaemia...
news
Amgen receives positive CHMP opinion for use of Repatha for the treatment of high cholesterol
22 May 2015 | By Victoria White
The CHMP has adopted a positive opinion for the marketing authorisation of Amgen’s Repatha for use in certain patients with high cholesterol...
news
Dyslipidemia treatment market value will approach $38 billion by 2023
20 May 2015 | By Victoria White
The global treatment market for dyslipidemia will more than double from $15.4 billion in 2013 to an estimated $37.9 billion by 2023, according to GlobalData...
news
FDA to review Amgen’s Repatha as a treatment for high cholesterol
30 April 2015 | By Victoria White
The FDA will review data supporting Amgen’s Biologics License Application (BLA) for Repatha (evolocumab) for the treatment of high cholesterol...
news
Amgen presents long-term data showing efficacy and safety of investigational cholesterol-lowering medication evolocumab across lipid And LDL-C levels
Amgen (NASDAQ:AMGN) has announced new data from three separate analyses of Phase 2 and 3 studies evaluating evolocumab, a novel investigational low-density lipoprotein cholesterol (LDL-C)-lowering medication.
news
Sanofi and Regeneron announce new results from six Phase 3 trials showing that alirocumab significantly reduced LDL cholesterol
19 November 2014 | By Sanofi / Regeneron Pharmaceuticals
Sanofi and Regeneron Pharmaceuticals, Inc. today announced new detailed positive results from six Phase 3 ODYSSEY trials that showed alirocumab significantly reduced low-density lipoprotein cholesterol (LDL-C, or "bad" cholesterol). Alirocumab is an investigational fully human monoclonal antibody targeting the protein PCSK9 (proprotein convertase subtilisin/kexin type 9) that is being evaluated…
news
Biologics to Complement Statins in Cholesterol Treatment Space, says GlobalData Analyst
12 November 2014 | By GlobalData
Biologics will play an influential role in shaping the future of cardiovascular (CV) drug treatment, as these and other emerging therapies will compete for patients who cannot tolerate statins, or for whom statin therapy alone is insufficient, according to an analyst with research and consulting firm GlobalData...
news
Sanofi and Regeneron present detailed positive results from four pivotal Alirocumab trials at ESC Congress 2014
2 September 2014 | By Sanofi
Sanofi and Regeneron Pharmaceuticals, Inc. announced detailed positive results from four Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia...
news
Amgen announces positive top-line results from Phase 3 YUKAWA-2 trial of evolocumab
28 August 2014 | By Amgen
...in combination with statins in Japanese patients with high cardiovascular risk and high cholesterol.
news
New detailed Phase 3 data show Amgen’s novel investigational cholesterol-lowering medication evolocumab significantly reduced LDL Cholesterol
2 June 2014 | By Amgen
...in patients with a rare and serious genetic disorder that causes high cholesterol.
news
Amgen announces positive top-line results from Phase 3 TESLA trial of evolocumab in patients with homozygous familial hypercholesterolemia
17 March 2014 | By Amgen
Study meets primary endpoint of LDL cholesterol reduction First phase 3 data of a pcsk9 inhibitor in patients with homozygous familial hypercholesterolemia - a rare and serious disease...
